CL429 VacciGrade™ - TLR2 & NOD2-based Adjuvant

Pam2C-conjugated murabutide

ABOUT

Dual TLR2 & NOD2 agonist

CL429 is a chimeric compound that stimulates both TLR2 and NOD2. This compound is composed of murabutide (NOD2 ligand) covalently linked to Pam2C (TLR2 ligand) via a spacer.

CL429 was shown to induce synergistic human DC maturation in vitro and to significantly enhance both systemic and mucosal immunity against a vaccine antigen. The very potent adjuvant activity of CL429 is associated with no apparent toxicity. This activity seems to be mediated by an optimal DC maturation process, which induces strong B and T cell stimulation and autophagy.

 

CL429 VacciGrade™ is a high-quality pre-clinical grade.

All products are for internal research use only, and not for human or veterinary use.

VacciGrade™

VacciGrade™ is a high-quality pre-clinical grade, suitable for in vivo studies. VacciGrade™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The absence of  bacterial contamination is assessed by a sterility test using a pharmacopeia-derived assay.

SPECIFICATIONS

Specifications

Source
Synthetic
Synonyms
Pam2C-Aca-Benzyl-Murabutide
Chemical formula

C74H128N6O17S

Molecular weight
1405.90 g/mol
Working concentration

20 - 50 µg/mouse

Solubility

5 mg/ml in DMSO

Appearance (form)
Lyophilized pellet
Appearance (color)
White
Sterility

0.2 µm filtration, Sterility guaranteed

Quality control

Each lot is functionally tested and validated using cellular assays.

CONTENTS

Contents

  • Product: 
    CL429 VacciGrade™
  • Cat code: 
    vac-c429
  • Quantity: 
    5 mg
Includes:

10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C

    Caution:

    • Do not store in plastic tubes

Details

CL429 is a chimeric compound that stimulates both TLR2 and NOD2. This compound is composed of murabutide (NOD2 ligand) covalently linked to Pam2C (TLR2 ligand) via a spacer [1].

NOD2 is highly expressed at the mucosal level [2, 3] and its activation induces the production of proinflammatory cytokines and autophagy [4, 5].

TLR2 appears to have a special role in T cell polarization and differentiation [6], mucosal homing receptor expression, and IgA production by human B cells [7].

CL429 was shown to induce synergistic human DC maturation in vitro and to significantly enhance both systemic and mucosal immunity against a vaccine antigen [1].

The very potent adjuvant activity of CL429 is associated with no apparent toxicity. This activity seems to be mediated by an optimal DC maturation process, which induces strong B and T cell stimulation and autophagy [1].

 

1. Pavot V. et al., 2014. Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity. J Immunol. 193(12):5781-5.
2. Geddes K. et al., 2009. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov. 8(6):465-79.
3. Kobayashi KS. et al., 2005. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 307(5710):731-4.
4. Rubino SJ. et al., 2012. Nod-like receptors in the control of intestinal inflammation. Curr Opin Immunol. 24(4):398-404.
5. Cooney R. et al., 2010. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 16(1):90-7.
6. Borrello S. et al., 2011. TLR2: a crossroads between infections and autoimmunity? Int J Immunopathol Pharmacol. 24(3):549-56.
7. Liang Y. et al., 2011. Toll-like receptor 2 induces mucosal homing receptor expression and IgA production by human B cells. Clin Immunol. 138(1):33-40.

DOCUMENTS

Documents

CL429 VacciGrade™

Technical Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?